Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open Label, Non-randomized, Parallel Group, Pharmacokinetic Study in Subjects With Normal Renal Function, Moderate or Severe Renal Impairment Receiving a Single Dose of Oral 130 mg AZD3355

NCT00863161 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00863161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00863161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open Label, Non-randomized, Parallel Group, Pharmacokinetic Study in Subjects With Normal Renal Function, Moderate or Severe Renal Impairment Receiving a Single Dose of Oral 130 mg AZD3355
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2009
Completion date
February 28, 2010
Enrollment
23 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

reflux, renal excretion